Contrasting of Intra-Cellular Therapies Inc. (ITCI) and Denali Therapeutics Inc. (NASDAQ:DNLI)

Intra-Cellular Therapies Inc. (NASDAQ:ITCI) and Denali Therapeutics Inc. (NASDAQ:DNLI), both competing one another are Biotechnology companies. We will compare their dividends, analyst recommendations, profitability, institutional ownership, risk, earnings and valuation.

Valuation & Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Intra-Cellular Therapies Inc. N/A 0.00 155.13M -2.84 0.00
Denali Therapeutics Inc. 129.16M 18.02 36.24M -1.45 0.00

Table 1 shows gross revenue, earnings per share and valuation of the two companies.

Profitability

Table 2 has Intra-Cellular Therapies Inc. and Denali Therapeutics Inc.’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Intra-Cellular Therapies Inc. 0.00% -31.1% -29.4%
Denali Therapeutics Inc. -28.06% -27.9% -24.7%

Liquidity

The Current Ratio of Intra-Cellular Therapies Inc. is 13.2 while its Quick Ratio stands at 13.2. The Current Ratio of rival Denali Therapeutics Inc. is 12.1 and its Quick Ratio is has 12.1. Intra-Cellular Therapies Inc. is better equipped to clear short and long-term obligations than Denali Therapeutics Inc.

Analyst Recommendations

The table shown features the ratings and recommendations for Intra-Cellular Therapies Inc. and Denali Therapeutics Inc.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Intra-Cellular Therapies Inc. 0 0 3 3.00
Denali Therapeutics Inc. 0 0 0 0.00

Intra-Cellular Therapies Inc. has a 101.19% upside potential and a consensus price target of $27.

Insider & Institutional Ownership

The shares of both Intra-Cellular Therapies Inc. and Denali Therapeutics Inc. are owned by institutional investors at 78.6% and 84.5% respectively. Insiders held 3.8% of Intra-Cellular Therapies Inc. shares. Comparatively, 0.1% are Denali Therapeutics Inc.’s share held by insiders.

Performance

In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Intra-Cellular Therapies Inc. 3.2% 12.54% -12.41% -37.21% -24.89% 18.96%
Denali Therapeutics Inc. -0.05% 15.48% 14.34% 22.14% 2.04% 6.53%

For the past year Intra-Cellular Therapies Inc. has stronger performance than Denali Therapeutics Inc.

Summary

On 6 of the 10 factors Denali Therapeutics Inc. beats Intra-Cellular Therapies Inc.

Intra-Cellular Therapies, Inc., a biopharmaceutical company, engages in developing novel drugs for the treatment of neuropsychiatric and neurodegenerative diseases and diseases of the elderly, including ParkinsonÂ’s and AlzheimerÂ’s disease. The company is developing its lead drug candidate, lumateperone, known as ITI-007, for the treatment of schizophrenia, bipolar disorder, behavioral disturbances in patients with dementia, depression, and other neuropsychiatric and neurological disorders. Lumateperone, a molecule, is in Phase III clinical development for the treatment of schizophrenia, bipolar depression, and agitation associated with dementia, including Alzheimer's disease. The company is also utilizing its phosphodiesterase platform and other proprietary chemistry platforms to develop drugs for the treatment of central nervous system and other disorders. Intra-Cellular Therapies, Inc. is headquartered in New York, New York.

Denali Therapeutics Inc., a biopharmaceutical company, engages in discovering and developing therapeutics for neurodegenerative diseases in the United States. The company's lead LRRK2 product candidates includes the DNL201, a small molecule inhibitor that is in Phase I clinical trials, as well as DNL151, a small molecule inhibitor, which is in preclinical development stage for the treatment of Parkinson's disease. It is also developing therapeutics for the treatment of Parkinson's, dementia with Lewy bodies, and multiple system atrophy; amyotrophic lateral sclerosis; and mucopolysaccharidosis type II patients. Denali Therapeutics Inc. has collaboration agreement with Takeda Pharmaceutical Company to develop and commercialize therapeutic product candidates for neurodegenerative diseases; and a strategic partnership with Lonza Pharma & Biotech to develop and produce biologic medicines for neurodegenerative diseases. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.

"

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.